Stage IV pancreatic ductal adenocarcinoma (PDAC) with synchronous liver metastasis: are there survival benefits in liver resection? A systematic review and meta-analysis

A partir d'une revue systématique de la littérature publiée jusqu'en avril 2023 (6 études), cette méta-analyse évalue la survie globale des patients atteints d'un adénocarcinome canalaire du pancréas avec métastases hépatiques synchrones en fonction du traitement reçu (avec ou sans chirurgie)

Résumé en anglais

Objective: Metastatic PDAC has a very poor prognosis, and surgery has a limited role. The study aims to evaluate the OS of patients with PDAC and synchronous liver metastasis who undergo surgical therapy (ST) versus non-surgical therapies (NST).

Methods: We performed a random effects meta-analysis. Inclusion criteria were: PDAC histology; studies reporting technically resectable cases with liver metastasis and survival data; absence of extra-hepatic disease. The primary endpoint was to evaluate OS. Results were reported as HR and 95% CI. We performed a meta-regression analysis to identify factors influencing heterogeneity. We analyzed key covariates in order to predict how changes in these factors affect HR.

Results: Six studies were included. The OS was significantly better in group ST than NST, with HR= 0.41 (95% CI: 0.32-0.52). Heterogeneity was high (I2 = 64.50%). As the rate of patients who underwent postoperative CT in the ST group decreased, the difference between the two groups decreased (